SERCA inhibition induces a G0/G1 arrest in NOTCH1-mutated human leukemia cells, introducing SERCA as a potential therapeutic target in cancers associated with NOTCH1 mutations (Roti et al., 2013). The gene discussed is NOTCH1; the disease is cancer.